Cumberland Pharmaceuticals’ ifetroban receives FDA Fast Track Designation for DMD-associated heart disease, the leading cause of death in Duchenne muscular dystrophy. Phase 2 FIGHT DMD trial data show 5.4% LVEF improvement, disease stabilization, and strong safety profile.
Written By: Pharmacally Medical News Desk
Cumberland Pharmaceuticals Inc. has received Fast Track Designation from the U.S. Food and Drug Administration for ifetroban, its oral investigational therapy aimed at treating Duchenne muscular dystrophy (DMD)–associated heart disease, a leading cause of death in these patients.
Commenting on the milestone, Cumberland’s founder and CEO A.J. Kazimi said the Fast Track Designation reflects the urgent and critical unmet need in DMD heart disease and enables closer collaboration with the FDA to advance ifetroban efficiently.
Phase 2 FIGHT DMD trial: topline results
The FDA decision is supported by positive data from the Phase 2 FIGHT DMD trial (NCT03340675) which evaluated oral ifetroban in patients with DMD-related heart disease.
Topline findings over 12 months of treatment showed:
- A 5.4% absolute improvement in left ventricular ejection fraction (LVEF), a key measure of heart pumping function
- Evidence of disease stabilization or improvement, contrasting with the expected progressive decline typically seen in DMD cardiomyopathy
- A favorable safety and tolerability profile, with no new safety signals reported during the study period.
These results are notable in a condition where cardiac function usually worsens over time despite standard care.
About Ifetroban and prior regulatory milestones
Ifetroban is a once-daily, oral thromboxane receptor antagonist designed to target key inflammatory and fibrotic pathways involved in DMD-associated heart disease. By blocking thromboxane signalling, the drug aims to reduce cardiac inflammation and fibrosis, processes that contribute to progressive cardiomyopathy in Duchenne muscular dystrophy.
The Fast Track decision follows earlier Orphan Drug Designation and Rare Pediatric Disease Designation for ifetroban in DMD heart disease. Together, these designations strengthen the regulatory pathway and underscore the lack of approved therapies specifically targeting cardiac complications in DMD.
Cumberland is positioning ifetroban as a heart-focused therapy, distinct from muscle-directed DMD treatments such as exon-skipping or gene therapies, which to date have not demonstrated meaningful cardiac benefit.
DMD heart disease
Duchenne muscular dystrophy is a rare, fatal pediatric disorder caused by mutations in the dystrophin gene, affecting roughly 1 in 3,500–5,000 male births. While skeletal muscle weakness is the most visible feature, heart disease is the leading cause of mortality in DMD.
Cardiac damage often begins early and progresses unpredictably. Current management relies on corticosteroids and conventional heart medications to reduce cardiac stress, but these approaches do not specifically target the underlying disease process and have not been shown to improve survival. As no therapy is currently approved specifically for DMD-related heart disease.
Fast Track status is reserved for therapies that address serious or life-threatening conditions with unmet medical need. The designation allows for more frequent FDA interactions, earlier regulatory guidance, and the option to submit sections of a marketing application on a rolling basis.
References
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program, 04 February 2026, https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-fast-track-designation
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease, 04 February 2025, https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-breakthrough-results-phase
Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy (DMD), ClinicalTrials.gov ID NCT03340675, https://clinicaltrials.gov/study/NCT03340675